New BioTy™ Antimicrobial Surface Coating Technology will enable cost-effective infection control in spine and orthopaedic implants.
Infection control is a critical concern in healthcare. Nowhere is that more evident than with surgical implants, where the body's own defense mechanism will coat an implant with a "Biofilm" layer. Biofilm is known to resist antibiotic therapy, the primary treatment option in infection control. As a result, the cost impact of Biofilm is significant. In fact, hospital associated infections caused from Biofilm on medical devices is estimated to cost the US healthcare system annually. Recent information released by the CDC shows that surgical site infection rates accounted for 31% of all healthcare associated infections among hospitalized patients. In part, this is due to the widespread production, use and misuse of antibiotics, which have contributed to the next generation of drug resistant infectious organisms, commonly called "Superbugs".